Emerging preclinical pharmacological targets for Parkinson’s disease

Sandeep Vasant More and Dong-Kug Choi _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:29835-29863. https://doi.org/10.18632/oncotarget.8104

Metrics: PDF 3381 views  |   HTML 4581 views  |   ?  


Sandeep Vasant More1 and Dong-Kug Choi1

1 Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, South Korea

Correspondence to:

Dong-Kug Choi, email:

Keywords: dopaminergic, Parkinson’s disease, pharmacological targets, neuroprotection, preclinical

Received: October 08, 2015 Accepted: February 08, 2016 Published: March 15, 2016


Parkinson’s disease (PD) is a progressive neurological condition caused by the degeneration of dopaminergic neurons in the basal ganglia. It is the most prevalent form of Parkinsonism, categorized by cardinal features such as bradykinesia, rigidity, tremors, and postural instability. Due to the multicentric pathology of PD involving inflammation, oxidative stress, excitotoxicity, apoptosis, and protein aggregation, it has become difficult to pin-point a single therapeutic target and evaluate its potential application. Currently available drugs for treating PD provide only symptomatic relief and do not decrease or avert disease progression resulting in poor patient satisfaction and compliance. Significant amount of understanding concerning the pathophysiology of PD has offered a range of potential targets for PD. Several emerging targets including AAV-hAADC gene therapy, phosphodiesterase-4, potassium channels, myeloperoxidase, acetylcholinesterase, MAO-B, dopamine, A2A, mGlu5, and 5-HT-1A/1B receptors are in different stages of clinical development. Additionally, alternative interventions such as deep brain stimulation, thalamotomy, transcranial magnetic stimulation, and gamma knife surgery, are also being developed for patients with advanced PD. As much as these therapeutic targets hold potential to delay the onset and reverse the disease, more targets and alternative interventions need to be examined in different stages of PD. In this review, we discuss various emerging preclinical pharmacological targets that may serve as a new promising neuroprotective strategy that could actually help alleviate PD and its symptoms.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8104